Placebo
DrugPlacebo will be volume- matched and administered subcutaneously (SC) once weekly.
NCT Number: NCT06525935
This is a multi-center, randomized, double-blind, placebo-controlled, parallel group dose-finding study to evaluate the efficacy and safety of enicepatide at low, middle, and high doses in participants with obesity or who are overweight with at least one weight-related comorbidity.
Looking for future studies?
Notify Me18 year–75 year
All sexes
Interventional
Phase 2
Alabama Clinical Therapeutics, LLC, Birmingham, Alabama, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Placebo will be volume- matched and administered subcutaneously (SC) once weekly.
Enicepatide will be administered subcutaneously (SC) once weekly at the randomized dosing regimen.
Other names: CT-388, RO7795068, RG6640
Time frame: Baseline to Week 48
Time frame: Baseline and Week 48
Time frame: Baseline to Week 48
Time frame: Baseline to Week 48
Time frame: Baseline to Week 48
Time frame: Baseline to Week 48
Time frame: Baseline to Week 48
Time frame: Baseline to Week 48
Time frame: Baseline to Week 48
Time frame: Baseline to Week 48
Time frame: Baseline to Week 48
Time frame: Baseline to Week 48
Time frame: Baseline to Week 48
Time frame: Baseline to Week 48
Time frame: Baseline to Week 48
Time frame: Baseline and Week 48
Carmot Therapeutics, Inc.
Industry
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of Once-Weekly CT-388 Administered for 48 Weeks to Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05929079
Apnea, Body Weight
Anniston, Alabama, United States
View Trial DetailsNCT00342732
Body Weight, Nutrition Disorders
Phoenix, Arizona, United States
View Trial DetailsNCT00445627
Body Weight, Diabetes Mellitus
Bethesda, Maryland, United States
View Trial DetailsNCT06904105
Body Weight, Nutrition Disorders
Beijing, Beijing Municipality, China
View Trial Details